Bisoza 5/Bisoza 10/Bisoza 15 Dosage/Direction for Use

Schizophrenia: Usual Dose: Adults: Aripiprazole is indicated for acute and maintenance treatment of Schizophrenia.
The recommended starting and target dose for aripiprazole tablets is 10 mg/day or 15 mg/day administered on a once-a-day schedule without regard to meals. Aripiprazole tablets have been systematically evaluated and shown to be effective in a dose range of 10 mg/day to 30 mg/day; however, doses higher than 10 mg/day or 15 mg/day were not more effective than 10 mg/day or 15 mg/day. Dosage increases should not be made before 2 weeks, the time needed to achieve steady state.
Adolescents: Aripiprazole indicated for the treatment of Schizophrenia in adolescents 13 to 17 years of age.
The recommended target dose of aripiprazole tablets is 10 mg/day. Aripiprazole was studied in pediatric patients 13 to 17 years of age with Schizophrenia at daily doses of 10 mg and 30 mg. The starting daily dose of aripiprazole tablets in these patients was 2 mg, which was titrated to 5 mg after 2 days and to the target dose of 10 mg after 2 additional days. Subsequent dose increases should be administered in 5 mg increments. The 30 mg/day dose was not shown to be more efficacious than the 10 mg/day dose. Aripiprazole tablets can be administered without regard to meals.
Maintenance Therapy: Adults: While there is no body of evidence available to answer the question of how long a patient treated with aripiprazole should remain on it, systematic evaluation of patients with Schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer, were discontinued from those medications, and were then administered aripiprazole tablets 15 mg/day and observed for relapse during a period of up to 26 weeks, has demonstrated a benefit of such maintenance treatment. Patients should be periodically reassessed to determine the need for maintenance treatment.
Pediatric Patients: The efficacy of aripiprazole for the maintenance treatment of Schizophrenia in the pediatric population has not been evaluated.
Or as directed by the physician.